Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.40 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 4/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7744290 | 1.00 | PLA2G2A (0.46) | PLA2G2ABLMGPR84PTGS2MTNR1A | |
| SCHEMBL21611346 | 1.00 | PLA2G2A (0.46) | PLA2G2ABLMGPR84PTGS2MTNR1A | |
| SCHEMBL11940223 | 0.92 | ALDH1A1 (0.44) | PLA2G2ABLMGPR84PTGS2MTNR1A | |
| SCHEMBL24495927 | 0.92 | PLA2G2A (0.58) | PLA2G2ABLMMAOAMAOBCNR2 | |
| SCHEMBL13740891 | 0.84 | ALDH1A1 (0.48) | PLA2G2ABLMPTGS2ALDH1A1MAOA | |
| SCHEMBL5041111 | 0.84 | GPR84 (0.41) | PLA2G2ABLMGPR84PTGS2MTNR1A | |
| SCHEMBL31746156 | 0.83 | MTNR1A (0.63) | MTNR1AMTNR1BMAOBSLC16A3SLC16A1 | |
| SCHEMBL12836982 | 0.82 | PTGS2 (0.39) | PLA2G2ABLMGPR84PTGS2MTNR1A | |
| SCHEMBL21614137 | 0.81 | SLC16A3 (0.43) | PTGS2SLC16A3SLC16A1 | |
| SCHEMBL23273055 | 0.81 | SLC16A3 (0.43) | PTGS2SLC16A3SLC16A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112703180-B | Amphiphilic mesogenic organic dyes for customized reflective low dimensional materials | 索邦大学 | 2024-01-23 | — | — | CN | disclosed |
| US-11407743-B2 | Amphiphilic and mesogenic organic dyes for tailor-made reflective low-dimensional materials | SORBONNE UNIVERSITE (FR) | 2022-08-09 | — | — | US | disclosed |
| EP-3818039-A1 | AMPHIPHILIC AND MESOGENIC ORGANIC DYES FOR TAILOR-MADE REFLECTIVE LOW-DIMENSIONAL MATERIALS | Centre National de la Recherche Scientifique (CNRS) (FR) | 2021-05-12 | — | — | EP | disclosed |
| US-20210122742-A1 | Amphiphilic and Mesogenic Organic Dyes for Tailor-Made Reflective Low-Dimensional Materials | UNIVERSITÉ PARIS CITÉ (FR) | 2021-04-29 | — | — | US | disclosed |
| WO-2020008052-A1 | AMPHIPHILIC AND MESOGENIC ORGANIC DYES FOR TAILOR-MADE REFLECTIVE LOW-DIMENSIONAL MATERIALS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122742-A1 | Amphiphilic and Mesogenic Organic Dyes for Tailor-Made Reflective Low-Dimensional Materials | MITF, LRAT, APOL1 | PLA2G2A 1675/4885BLM 521/4885GPR84 1671/4885 |
| US-11407743-B2 | Amphiphilic and mesogenic organic dyes for tailor-made reflective low-dimensional materials | MITF, LRAT, APOL1 | PLA2G2A 1675/4885BLM 521/4885GPR84 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.